NakamotoH.Encapsulating peritoneal sclerosis–a clinician's approach to diagnosis and medical treatment.Perit Dial Int2005; 25(Suppl 4): S30–8.
2.
KawaguchiY., KawanishiH., MujaisS., TopleyN., OreopoulosD.G.Encapsulating peritoneal sclerosis: Definition, etiology, diagnosis, and treatment. International society for peritoneal dialysis ad hoc committee on ultrafiltration management in peritoneal dialysis.Perit Dial Int2000; 20(Suppl 4): S43–55.
3.
GuestS.Hypothesis: Gender and encapsulating peritoneal sclerosis.Perit Dial Int2009; 29: 489–91.
4.
BrownM.C., SimpsonK., KerssensJ.J., MactierR.A.Encapsulating peritoneal sclerosis in the new millennium: A national cohort study.Clin J Am Soc Nephrol2009; 4: 1222–9.
5.
SummersA.M., AbrahamsA.C., AlscherM.D., BetjesM., BoeschotenE.W., BraunN.A collaborative approach to understanding eps: The european perspective.Perit Dial Int2011; 31: 245–8.
6.
KawanishiH., MoriishiM., IdeK., DohiK.Recommendation of the surgical option for treatment of encapsulating peritoneal sclerosis.Perit Dial Int2008; 28(Suppl 3): S205–10.
GrobnerT.Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?Nephrol Dial Transplant2006; 21: 1104–8.
13.
ThomsenH.S., MorcosS.K., DawsonP.Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?Clin Radiol2006; 61: 905–6.
14.
GoffinE., SchroederJ.A., WeingartC., DecleireP.Y., CosynsJ.P.Absence of gadolinium deposits in the peritoneal membrane of patients with encapsulating peritoneal sclerosis.Nephrol Dial Transplant2010; 25: 1334–9.
15.
BraunN., FritzP., BieggerD., KimmelM., ReimoldF., UlmerC.Difference in the expression of hormone receptors and fibrotic markers in the human peritoneum— implications for therapeutic targets to prevent encapsulating peritoneal sclerosis.Perit Dial Int2011; 31: 291–300.
16.
SchroederJ.A., WeingartC., CorasB., HausserI., ReinholdS., MackM.Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease.Clin J Am Soc Nephrol2008; 3: 968–75.
17.
LatusJ., UlmerC., FritzP., RettenmaierB., BieggerD., LangT.Phenotypes of encapsulating peritoneal sclerosis—macroscopic appearance, histologic findings, and outcome.Perit Dial Int2013; 33(5): 495–502.
18.
MarckmannP., SkovL., RossenK., DupontA., DamholtM.B., HeafJ.G.Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.J Am Soc Nephrol2006; 17: 2359–62.
19.
MendozaF.A., ArtlettC.M., SandorfiN., LatinisK., Piera-VelazquezS., JimenezS.A.Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature.Semin Arthritis Rheum2006; 35: 238–49.
